A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
暂无分享,去创建一个
K. Goto | M. Maemondo | M. Nishio | T. Seto | T. Tamura | T. Hida | H. Yoshioka | N. Katakami | N. Yamamoto | K. Chikamori | T. Kozuki | T. Fukuyama